FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Lundbeck, Otsuka's Rexulti wins FDA nod for Alzheimer's agitation

Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease

Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® to Treat Agitation Associated with Alzheimer's Dementia

FDA Approves First-Ever Drug for Agitation Associated with Alzheimer's Dementia

First Treatment for Agitation Associated With Alzheimer Disease Dementia Approved by FDA

REXULTI® (brexpiprazole), Agitation associated with dementia due to Alzheimer's disease

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

First Treatment for Alzheimer's Agitation Approved by FDA

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease